You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Illumina said it plans to pursue a permanent injunction against BGI in the UK until the four patents expire — three in 2023 and one in 2027.
In their complaint the plaintiffs claimed Illumina fraudulently obtained two US patents by concealing a reference from the patent office.
In Nature this week: computational tool for the hybrid de novo assembly of human genomes, and more.
BGI will have a chance to depose up to nine inventors of patents assigned to Illumina as part of a lawsuit over IP related to sequencing-by-synthesis chemistry.
A US District Court will prevent BGI from distributing and promoting certain sequencing instruments that allegedly infringe Illumina patents.
Illumina had argued that Complete Genomics' patent covering two-color sequencing-by-synthesis chemistry was obvious, but the US PTAB disagreed.
The researchers said a functional investigation of the virus' unknown transcripts and RNA modifications will elucidate its life cycle and pathogenicity.
Under the terms of the non-exclusive agreement, the companies have made Diagenode's D-Plex library preparation products available on MGI's sequencing platforms.
According to the complaint, the allegedly infringing products include all those that use nucleotides with a 3’-O-azidomethyl blocking group.
At the Advances in Genome Biology and Technology meeting this week, several MGI customers reported results from the DNBSeq-G400.
Politico notes that the Biden Administration has not yet nominated a permanent Food and Drug Administration commissioner.
Anthony Fauci also informed the World Health Organization executive board that the US would be joining the COVAX initiative, according to CNBC.
A new preprint suggests some SARS-CoV-2 variants could affect the effectiveness of current vaccines, the Associated Press reports.
In Nature this week: Australian lungfish provides details on the movement of vertebrate life from water to land, and more.